The newest drugs for the treatment of multiple sclerosis include Briumvi, Ponvory, Kesimpta, Bafiertam, Zeposia, Vumerity, Mavenclad, Mayzent, and Ocrevus.

Multiple sclerosis (MS) is a neurological disease that affects the brain and spinal cord. In MS, the body's immune system attacks the protective myelin sheaths that cover nerve fibers, causing areas of scarring called sclerosis.

MS is a lifelong illness. It can follow one of several different patterns:

• Relapsing-Remitting MS (RRMS). The most common form of multiple sclerosis characterized by temporary periods of relapses and remissions.
• Secondary-Progressive MS (SPMS). Most people who are diagnosed with RRMS will transition to SPMS at some stage. In SPMS, symptoms worsen more steadily over time, with or without the occurrence of relapses and remissions.
• Primary-Progressive MS (PPMS). An uncommon form of MS characterized by slowly worsening symptoms from the onset, with no relapses or remissions.
• Progressive-Relapsing MS (PRMS). A rare form of MS characterized by a steadily worsening disease state from the onset.

Latest FDA Approvals for Multiple Sclerosis